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Summary 
We studied the effects of various chemokines including neutrophil-activating peptide 2 (NAP-2), 
[3-thromboglobulin ([3-TG),  platelet factor 4  (PF-4),  melanoma growth stimulating activity 
(GRO), ~/interferon-induced protein (IP-10), regulated on activation, normal T expressed and 
secreted (RANTES), macrophage inflammatory protein lot (MIP-lot), MIP-1 [3, and monocyte 
chemotactic protein 1 (MCP-1) on Immunoglobulin (IgE) and IgG4 production by human B 
cells.  None  of these chemokines with or without interleukin (IL-4), anti-CD40  or -CD58 
monoclonal antibody (mAb), induced IgE and IgG4 production by B cells from nonatopic do- 
nors. However, RANTES and MIP-lot selectively enhanced IgE and IgG4 production in- 
duced by IL-4 plus anti-CD40 or -CD58 mAb without affecting production of IgM, IgG1, 
IgG2, IgG3, IgA1, or IgA2, whereas other chemokines failed to do so. Enhancement of IgE 
and IgG4 production by RANTES and MIP-lot was specifically blocked by anti-RANTES 
mAb and anti-MIP-lot antibody (Ab),  respectively, whereas anti-IL-5 mAb, anti-IL-6 mAb, 
anti-IL-10 Ab, anti-IL-13 Ab, and anti-tumor necrosis factor-6~ mAb failed to do so. Purified 
surface IgE positive (slgE +) and sIgG4  + B cells generated either in vitro or in vivo spontane- 
ously produced IgE and IgG4, respectively, whereas slgE- and sIgG4- B cells failed to do so. 
RANTES and MIP-lot enhanced spontaneous IgE and IgG4 production in slgE + and sIgG4  + 
B cells, respectively, whereas neither RANTES nor MIP-lot did so in sIgE- or slgG4- B cells. 
Purified sIgE + and sIgG4  +, but not sIgE- or slgG4- B cells, generated in vitro and in vivo ex- 
pressed  receptors for R_ANTES and MIP-lot, whereas they failed to express receptors for other 
chemokines. These findings indicate that RANTES and MIP-lot enhance IgE and IgG4 pro- 
duction by directly stimulating slgE + and slgG4 + B cells. 
H 
uman IgE and IgG4 production is regulated by vari- 
ous  cytokines and factors.  IL-4  and  IL-13  induced 
IgE and IgG4 production in mononuclear cells or in B cells 
stimulated with anti-CD40 mAb by isotype switching (1-3). 
IL-5, -6,  -9,  -10,  and TNF-Ot  enhance IL-4- and IL-13- 
induced IgE and IgG4 production (1-6),  whereas IFN-ot, 
IFN-y,  TGF-[3,  and  IL-12  inhibit  their  production  de- 
pending on the condition of culture (1, 4, 6, 7). Moreover, 
IL-4 plus anti-CD58 mAb also induced IgE production by 
purified B  cells, and this production was IFN-~/  and IL-6 
independent  (8). We  have  also  reported  that some  neu- 
ropeptides selectively modulated IL-4 induced and sponta- 
neous IgE and IgG4 production, which was not mediated 
by these cytokines (9, 10). 
The chemokines consists of ot subfamily members includ- 
ing  IL-8,  melanoma growth-stimulating activity (GRO), 
neutrophil-activating peptide 2 (NAP-2),  [3-thromboglob- 
ulin  ([3-TG),  ~  interferon-induced protein  (IP-10),  and 
platelet factor 4 (PF-4), and [3 subfamily members including 
regulated  on  activation,  normal  T  expressed  and  secreted 
(RANTES), macrophage inflammatory  protein lot (MIP-lot), 
MIP-I[3,  and monocyte chemotactic protein  1  (MCP-1) 
(11). Recently, it has been reported that these chemokines 
act on various cell types, including neutrophils, eosinophils, 
basophils,  monocytes, myeloid progenitors,  and T  and B 
cells (11-15).  In addition, we have found that IL-8 selec- 
tively inhibited IgE and IgG4 production induced by IL-4 
(16).  Here,  we  demonstrate that R_ANTES  and MIP-lot 
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other chemokines fail to do so. 
Materials and Methods 
Reagents.  The following recombinant human cytokines and 
Abs were kindly provided by companies noted previously (2, 4): 
IL-4 and rabbit anti-IL-4 Ab  (Ono Pharmaceutical Company, 
Osaka, Japan), and IL-2 and IFN-o~ (Takeda Chemical Industries, 
Osaka, Japan).  Recombinant human IL-13 was purchased  from 
Pepro Tech Inc. (Rocky Hill, NJ) (2). Recombinant human IL-8 
and mouse IgG1 anti-IL-8 mAb were obtained from Sandoz Re- 
search Institute (Vienna, Austria) (16). Recombinant  human IL-10, 
-6,  -12,  TGF-[3,  R.ANTES,  GRO,  MIP-lo~,  MIP-I~3,  and 
MCP-1, and mouse IgG1 anti-IL-5, anti-IL-6, anti-TNF-c~  mAb, 
anti-RANTES mAb, and goat anti-lL-10 and anti-MIP-lc~ Ab 
were  purchased  from R&D  Systems,  Inc.  (Minneapolis,  MN). 
Recombinant human NAP-2, PF-4, highly purified native hu- 
man I3-TG, IP-10, mouse IgM anti-CD40 mAb (BL-C4),  mouse 
IgG2a anti-CD58 mAb (BRIC5), and rabbit anti-IL-13 Ab were 
purchased  from Cosmo Bio Co.  (Tokyo, Japan)  (2, 4,  16). The 
culture medium was DME, supplemented with Ham's Nutrient 
(DME/F-12) (Sigma Chemical Co., St. Louis, MO), 0.5% BSA, 
and 50/~g/ml transferrin  (2). 
Cell Cultures.  Tonsillar mononuclear cells were obtained from 
nonatopic donors  (serum  lgE level <50 U/ml) and atopic  pa- 
tients (serum IgE level 1,578-12,259 IU/ml). Highly purified B 
cells were separated  by SRBC rosetting,  followed by L-leucine 
methyl ester  incubation as described  previously (2). Purified B 
cell fractions  contained >98% CD20 § B  cells. Purified B  cells 
were depleted of surface IgE positive  (slgE  +) and slgG4  + B cells 
by panning. The percentage  of slgE §  and slgG4  + B  cells was 
<0.1%. The slgE-, slgG4- B cells were cultured (2  X  I0S/0.2 
rnl/well) in U-bottomed microtiter plates  (Costar  Corp.,  Cam- 
bridge, MA) for 14 d in the presence or absence of various factors 
with or without Abs as described  in Results. All the Abs to cy- 
tokines were used at 10 I~g/ml, because anti-IL-5 mAb, anti-IL-6 
mAb, anti-IL-10 Ab, anti-IL-13 Ab, and anti-TNF-c~ mAb (all at 
10  p,g/ml)  completely neutralized induction of [gE  and  IgG4 
production by IL-5 (100 ng/ml), IL-6 (100 ng/ml), IL-10 (100 
ng/ml), IL-13 (500 ng/ml), and TNF-~ (50 ng/ml), respectively 
(2,  4,  6).  In some  experiments, purified slgE-, slgG4- B  cells 
were cultured with [L-4 (1,000 U/ml) plus anti-CD40 mAb (0.1 
p,g/ml)  or IL-4 plus anti-CD58 mAb (0.1 p.g/ml)  for 5-7 d, and 
then slgE +, slgE-, slgG4  +, and slgG4- B ceils were purified by 
panning (2, 4). Alternatively, slgE +, slgE-, slgG4  +, and slgG4- 
B  cells were purified from tonsillar B cells of atopic  patients by 
panning. Purified slgE +  and slgG4  + B  cell  fractions  contained 
>98% sIgE  + B cells and >98% slgG4  + B cells, respectively (2, 4). 
Purified slgE § and slgG4 + B cells were cultured (2 ￿  104/0.2 ml/ 
well) for 14 d as described  in Results.  The amounts oflgE, IgG 
subclasses, IgM, and IgA subclasses in the supernatants were de- 
termined by ELISA (2, 4). Results were expressed as the means -+ 
1 SD of triplicate cukures from one experiment, representative  of 
four or five. 
In some experiments, slg  + and slg- B cells were tested for the 
binding of chemokines by immunofluorescence using biotiny- 
lated  chemokines,  as  previously reported  (6,  17). The  mean 
flourencence intensity (MFI) value ofbiotinylated ligand-specific 
binding, determined after subtraction of the nonspecific  binding 
in the presence  of a 100-fold excess of unlabeled ligand, was ex- 
pressed as AMFI (6,  17). Binding (AMFI,  n  =  4) of RANTES, 
MIP-lo~, IP-10, MIP-11~, and MCP-1 in purified human mono- 
cytes was 76 +  14, 68 -  20, 58 +  21, 72 +  17, and 61  +  18, re- 
spectively, whereas binding (AMFI, n =  4) of NAP-2, [3-TG, PF-4, 
and GRO in purified human neutrophils was 92 +  31, 89 -+ 27, 
80 -+ 16, and 79 -+ 22, respectively. 
Results  and Discussion 
Preliminary experiments  showed that none of the chemo- 
kines  (1  pM-1  IxM) with  or  without  IL-4,  anti-CD40 
mAb, or anti-CD58 mAb induced IgE (<0.3 ng/ml), IgG4 
(<0.3 ng/ml), or other Ig (data not shown) production by 
purified B cells. However, as shown in Fig.  1, A and B, of 
the various chemokines tested, RANTES and MIP-I(x en- 
hanced  IgE  and  IgG4  production  induced  by IL-4 plus 
anti-CD40 mAb in a dose-dependent fashion, but failed to 
enhance IgM, IgG1, IgG2, IgG3, IgA1, and IgA2 produc- 
tion  (Fig.  1,  C  and  D).  In  contrast,  none  of the  other 
chemokines, including NAP-2,  [3-TG,  PF-4, GILO, IP-10, 
MIP-I[3, and MCP-1  had any effect on the production of 
IgE, IgG4 (Fig. 1, A and B) or other Igs (data not shown) at 
any concentrations tested.  Similarly,  RANTES  and MIP- 
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Figure  1.  Effects  ofchemokines on Ig production. Nonatopic donors' 
IgE-, slgG4- B cells were cultured with IL-4 (1,000 U/m]) plus anti- 
CD40 mAb (0.1 ~g/ml) (A-D), or IL-4 plus anti-CD58 mAb (0.1 p~g/ 
ml)  (E-H). Medium (O)  or various concentrations of RANTES (H), 
MIP-lc~ (A), GRO (A), NAP-2 (~7), [3-TG (V), PF-4 ([]), IP-10 (R), 
MIP-ll3 (~), or MCP-1 (0) were added, and production oflgE (A and 
E), IgG4 (Band F), IgM, IgGl, and lgG2 (Cam] G), or IgG3, lgAl, and 
lgA2 (D and H) was determined. 
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plus anti-CD58 mAb, but did not enhance the production 
of other Igs (Fig.  1, E-H). None of NAP-2,  [~-TG,  PF-4, 
GP,.O,  IP-10,  MIP-113,  or MCP-1  had any effect on the 
production of IgE,  IgG4  (Fig.  1,  E  and F),  or other Igs 
(data not shown). In five experiments performed, the ranges 
of enhancement of IgE and IgG4 production by R_ANTES 
(100  nM)  and MIP-lci  (100  nM)  were  3.3-5.1-fold  and 
2.9-5.2-fold, respectively, in cultures stimulated with IL-4 
plus anti-CD40 mAb,  and 2.7-5.2-fold and 2.5-4.9-fold, 
respectively,  in  cultures  stimulated with  IL-4  plus  anti- 
CD58 mAb. 
We and others have previously reported that IL-4-pre- 
stimulated B cells produce IgE spontaneously in vitro after 
switching to slgE  + B cells (18, 19). Therefore, in this study, 
slgE-,  slgG4-  B  cells were prestimulated with IL-4 plus 
anti-CD40 mAb or IL-4 plus anti-CD58 mAb, and slgE +, 
slgG4 +, slgE-, and slgG4- B cells were purified. We also 
studied the effects of R_ANTES  and MIP-loe on in vivo- 
generated slgE §  and slgG4 § B  cells obtained from atopic 
patients. As shown in Fig. 2, A-C, RANTES and MIP-lci 
enhanced IgE production in slgE + B cells induced by IL-4 
plus anti-CD40 mAb,  IL-4 plus anti-CD58  mAb,  and in 
vivo, but failed to induce IgE production in slgE- B cells. 
Enhancement of IgE production by RANTES was specific, 
since  it was blocked by anti-R_ANTES  mAb but not by 
anti-MIP-lot Ab or control mouse IgG1  (data not shown). 
Conversely, enhancement of IgE production by MIP-lot 
was blocked by anti-MIP-lot Ab, but not by anti-RANTES 
mAb or control goat IgG (data not shown). Identical results 
were obtained for IgG4 production (Fig. 2, D-F). 
These findings indicate that R.ANTES and MIP-lot di- 
recdy stimulated slgE  +  and  slgG4  +  B  cells  generated in 
vitro and in vivo, but had no effect on slgE- and slgG4- B 
cells. Kinetic experiments showed that enhancement of IgE 
and IgG4 production could be detected on day 4 (Fig. 3). 
That enhancement was caused by stimulation of Ig produc- 
tion and not by proliferation of slgE + and slgG4 + B cells, 
since R_ANTES and MIP-lcc had no effect on cell number 
on any day tested (Fig. 3). 
We  and  others  have  reported  that  IL-6,  IL-10,  and 
TNF-c~ each enhances IgE and IgG4 production induced by 
IL-4 plus anti-CD40 mAb (4-6). As shown in Fig. 4 A, ad- 
dition of anti-IL-6 mAb and anti-IL-10 Ab each inhibited 
IgE and IgG4 production in slgE + and slgG4 + B cells, re- 
spectively, induced by IL-4 plus anti-CD40 mAb, whereas 
anti-TNF-Ix mAb,  IFN-oL, and IFN-~/  failed to do so.  In 
contrast, anti-IL-10 Ab and anti-TNF-o~ mAb each inhib- 
ited IgE and IgG4 production in those cells induced by IL-4 
plus anti-CD58 mAb, whereas anti-IL-6 mAb, IFN-cx, and 
IFN-~/  each failed to do so (Fig. 4 B). On the other hand, 
anti-IL-6 mAb, anti-IL-10 Ab, and anti-anti-TNF-0t mAb 
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Figure 2.  Effects  of RANTES or MIP- 
la on IgE and IgG4 production in slg  § or 
slg- B cells, slgE  + or slgE- B cells (A-C), 
and slgG4  + or slgG4- B  cells (D--F)  in- 
duced by IL-4 plus anti-CD40 mAb (A and 
D), IL-4 plus anti-CD58 mAb (B and E), or 
in  vivo  (C  and  F)  were  cultured  with 
RANTES (100 riM) or MIP-lcx (100 nM) 
in the presence or absence of Abs (10 ~g/ 
ml), and production oflgE (A-C) and IgG4 
(D-F) was determined. 25- 
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each inhibited IgE and lgG4 production in in vivo-gener- 
ated slgE + and slgG4  + B cells, although neither IFN-~x nor 
IFN-~/  inhibited  those  responses  (Fig.  4  C).  However, 
none  of  these  Abs  inhibited  enhancement  induced  by 
R.ANTES or MIP-lel (Fig. 4, A-C). None oflL-l[3, -2, -3, 
-7, or -9 at 300 U/ml, and none of IL-5, -11, -12, or -13 
at 500 ng/ml affected IgE and IgG4 production by slgE  + 
and slgG4  §  B  cells, respectively, in these  culture systems. 
Moreover, Abs to these cytokines also were without effects 
(<20% enhancement or inhibition). The effective neutral- 
izing effects  of endogenously produced cytokines with neu- 
tralizing Abs may be due to the FCS-free medium used in 
our cukure system, since FCS induced TNF-ci production 
Figure 3.  Kinetic  study of the effects of P,.ANTES and 
M[P-hx on slgE  + and slgG4  + B cells. Purified slgE  + B 
cells (A-C)  or slgG4  + B cells (D-F) induced by IL-4 
plus anti-CD40 mAb (A and D), IL-4 plus anti-CD58 
mAb (B and E) or in vivo (C and F) were cultured with 
medium, RANTES  (I00 nM), or MIP-lc~ (100 nM), 
and Ig production and cell number were determined on 
days 0-14. 
endogenously (20). We also measured IL-10 production by 
in  vivo--generated  sIgE +  and sIgG4  +  B  cells.  After 3  d  of 
culture,  IL-10  production  (picograms  per  milliliter)  by 
sIgE  + and sIgG4  + B  cells cultured with medium, R_ANTES 
(100 nM) and MIP-loL (100 nM) was 322 +  41 and 410 -+ 
62, 338  -  57 and 425  --- 31, and 309  +  48 and 402  +  55, 
respectively (n =  4). Similarly, neither RANTES nor MIP- 
1o~  induced mRNA  for IL-10 by PCP,.  (<20%  enhance- 
ment  of control by  densitometry).  Similar findings were 
observed in sIgE + and sIgG4  + B  cells induced by IL-4 plus 
anti-CD40  mAb,  or  by  IL-4  plus  anti-CD58  mAb  (our 
manuscript in preparation). 
Taken together, these findings indicate that the require- 
(A)  IL-4 + Anti-CD40  (B)  IL-4 + Anti-CD58  (C)  in  viva 
slgE*  B  slgG+*  B  slgE*  B  slgG+*  B  slgE*  B  slgG4*  B 
IgE  (ng/ml)  IgC.-~ (ng/ml)  IgE  (ng/ml)  IgG4 (ng/ml)  IgE  (ng/ml)  IgG+ (ng/ml) 
0  20  40  0  20  40  0  5  10  0  10  20  0  10  20  0  20  40  60 
Medium 
RANTES 
MIP-t u 
Y//////////~ 
:.:-..:-:,;.:~,  !.-:.;.;-:.;.:..~  Figure 4.  Effects  of various factors on enhance- 
ment of IgE and IgG4 production by RANTES 
and MIP-lot. Purified slgE  + B cells and slgG4  + B 
cells induced by IL-4 plus anti-CD40 +nAb (A), 
IL-4 plus anti-CD58 mAb (B), or in vivo (C) were 
cultured with medium, R_ANTES (100 nM)  or 
MIP-lcx (100 nM), and various  factors were added 
All the Abs were used at 10 lig/ml, and IFN-ot and 
IFN-~/ at 1,000 U/ml. After 14 d of culture, IgE 
and lgG4 production were determined. 
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tion in slgE + and slgG4 + B cells differed depending on the 
inductive  stimuli.  IL-6 and  IL-10,  but not  TNF-c~,  were 
required by slgE + and slgG4 + B cells induced by IL-4 plus 
anti-CD40 mAb, whereas IL-10 and TNF-cx, but not IL-6, 
were  required  by slgE +  and  slgG4  +  B  cells  induced  by 
IL-4 plus  anti-CD58  mAb.  In contrast,  IL-6,  IL-10,  and 
TNF-o~ were all required by slgE + and slgG4 + B cells gen- 
erated in vivo. These findings were consistent with previ- 
ous findings that anti-TNF-oL mAb failed to block IgE and 
IgG4  production  induced  by  IL-4 plus  anti-CD40  mAb 
(5), and that IL-6 did not affect IgE production induced by 
IL-4 plus anti-CD58 mAb (8). 
It is possible that the selective stimulation of slgE + and 
slgG4 +,  but not slgE-  and slgG4-  B  cells,  by R_ANTES 
and MIP-lc~ may be due to the presence or absence of re- 
ceptors on these cells. Therefore, expression of receptors for 
R_ANTES, MIP-lc~, and other chemokines was studied by 
binding assay. Binding  (AMFI) of RANTES in slgE  + and 
sIgG4  + B cells generated by IL-4 plus anti-CD40 mAb, IL-4 
plus anti-CD58 mAb, and in vivo, was 39  +  11  and 43  -+ 
16, 42  +  10 and 34 -+ 7, and 48  +  9 and 46 +  10, respec- 
tively  (n  =  4).  On  the  other  hand,  binding  (AMFI)  of 
MIP-I~ in  sIgE  +  and  sIgG4  +  B  cells  generated by IL-4 
plus  anti-CD40  mAb,  IL-4 plus  anti-CD58  mAb,  and  in 
vivo, was 37  +  12  and 42  •  7,  33  +  6 and 35  +  7,  and 
49 +  8  and  43  +  8,  respectively  (n  =  4).  In  contrast, 
none of the sIgE- and sIgG4- B cells generated in vitro or 
in vivo expressed receptors for RANTES or MIP-lo~ (<3 
AMFI)  (n =  4).  Moreover, none of sIgE  +,  sIgG4  +,  sIgE- 
or sIgG4- B  cells  expressed receptors for NAP-2,  [3-TG, 
PF-4, GRO, IP-10, MIP-I[3, or MCP-I(<3 ~flVIFI) (n =  4). 
In conclusion,  of v~rious chemokines tested,  RANTES 
and MIP-lcl selectively enhanced IgE and IgG4 production 
by directly stimulating sIgE  + and sIgG4  + B  cells generated 
in vitro and in vivo. The differences between  the effects 
of RANTES and MIP-I[3 and those of other chemokines 
were due to selective expression of receptors for RANTES 
and MIP-lo~ on sIgE  + and sIgG4  + B  cells.  In contrast, re- 
ceptors  for  other  chemokines  including  NAP-2,  [3-TG, 
PF-4, GRO, IP-10, MIP-I[3, and MCP-1  were not found 
on slgE + and slgG4  + B  cells.  This is not surprising.  It has 
been  reported  that  receptors  for RANTES  and MIP-lc~, 
but not  for MIP-113,  were found in  subpopulations of B 
cells (21,  22). We have previously reported that IL-8 selec- 
tively inhibited  IgE and IgG4 production (16).  Moreover, 
it is well established that chemokines do differ in their ef- 
fects depending  upon  target  cells  or  experimental condi- 
tions. For example, MIP-la inhibited colony formation of 
myeloid progenitor cells stimulated with steel factor, whereas 
MIP-I[3, GRO,  and NAP-2  failed do so  (13).  R.ANTES 
and MIP-I~t induced migration of eosinophils, while MIP-1 [3 
or MCP-1  did not (23). 
The  in  vivo  effects of RANTES  and  MIP-lot  on  IgE 
and IgG4 production remain to be elucidated. However, it 
has been reported that alveolar macrophages from patients 
with  asthma  produced  R.ANTES  and  MIP-lot,  and  that 
IgE  and  IgG4  concentrations  in  bronchoalveolar  lavage 
fluid  (BALF)  were  elevated  in  such  patients  (2,  24-26). 
Consistent with this, we found that R.ANTES and MIP-lcx 
concentrations in BALF were higher in asthmatic patients 
(58  +  13  pg/ml RANTES  and  48  +  9  pg/ml MIP-I~, 
n =  4) with elevated concentrations ofBALF lgE (2,785  + 
648 pg/ml) and IgG4 (738  -+ 149 ng/ml) than in asthmatic 
patients (24 +  5 pg/ml RANTES and 19 +  4 pg/ml MIP- 
lo~,  n  =  4)  without elevated concentrations  of BALF IgE 
(312  +  172 pg/ml) or IgG4 (129  -+ 42 ng/ml). 
We have previously reported that chemokine IL-8 selec- 
tively inhibits IgE and IgG4 production, whereas it also in- 
hibits  the growth of B  cells,  and that mRNA for IL-8RI 
and IL-8RII is found in B  cells  (16,  27,  28).  Conversely, 
the number of B  cells was found to be greatly increased in 
mice that lacked IL-8R homologue (15).  Taken together, 
these findings indicate that chemokines may play roles in Ig 
production by and growth  of B  cells.  Detailed molecular 
analysis  of the effects of RANTES and MIP-lot on B  cells 
is currently in progress. 
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